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The arachidonic acid-derived metabolite
12-(S)hydroxyeicosatetraenoic acid (12(S)-HETE), catalyzed by
12-lipoxygenase (12-LOX, ALOX12), exhibits a variety of
biological activities with implications in cardiovascular
disease. Previous studies have shown higher urinary
excretion of this metabolite in essential hypertension. The
aim of this study was to analyze the association of
polymorphisms in ALOX12 with hypertension and urinary
levels of 12(S)-HETE. We studied 200 patients with essential
hypertension (aged 5671 years, mean7s.e.m., 97 males) and
166 matched controls (aged 5471 years, 91 males). Out of six
polymorphisms in the coding region of ALOX12, only R261Q
determined a nonconservative amino-acid change and was
evaluated by polymerase chain reaction and restriction
digestion. Urinary 12(S)-HETE was measured in
Sep-Pack-extracted samples using specific enzyme-linked
immunosorbent assay. The distribution of genotypes of the
R261Q polymorphism was significantly different between
patients and controls: patients 92 (0.46) GG, 84 (0.42) GA, 24
(0.12) AA vs controls 56 (0.34) GG, 78 (0.47) GA, 32 (0.19) AA
(P¼ 0.030). On the contrary, no association was observed
for two intronic polymorphisms. The urinary excretion of
12(S)-HETE (ng/mg creatinine) was significantly higher in GG
homozygous patients (13.071.5) than in GA (8.271.8) or in
AA (871.5) patients (P¼ 0.018). These results indicate that a
nonsynonymous polymorphism in ALOX12 is associated to
essential hypertension and to urinary levels of 12(S)-HETE,
thus suggesting a role for this gene in this disease.
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The lipoxygenase (LOX) family includes a series of lipid
peroxidizing enzymes, which oxygenate free and esterified
polyenolic fatty acids to the corresponding hydroperoxide
derivates. The platelet-type 12-lipoxygenase (12-LOX)
catalyzes the transformation of arachidonic acid into
12-hydroperoxyeicosatetraenoic acid, which is reduced by
different mechanisms to 12-(S)hydroxyeicosatetraenoic acid
(12(S)-HETE).1 This enzyme was found to be expressed in
platelets, megakariocytes, and epithelial cells,1 but has been
found recently to expressed in a variety of tissues, such as
kidney tubule epithelial cells, heart, liver, and pancreas.2 A
dual origin for 12-hydroxyeicosatetraenoic acid (12-HETE)
has been described, since it also appears as an R stereo
isomer, 12(R)-hydroxyeicosatetraenoic acid, which is pro-
duced by cytochrome P-450,3 although a 12(R)-lipoxygenase
has been cloned from mice.4
A number of cardiovascular biological activities have been
reported for 12(S)-HETE and therefore support its participa-
tion in cardiovascular disorders.5 Vascular tissue exhibits
12-LOX activity and 12(S)-HETE has been demonstrated to
act as a vasoconstrictor in small renal arteries.6 Moreover,
12(S)-HETE has been shown to modulate the angiotensin
II-induced aldosterone secretion,7 and to influence the angio-
tensin II-induced intracellular calcium transients in cultured
rat vascular smooth muscle cells.8 Consistent with these
in vitro observations, in vivo studies have demonstrated a
role for 12(S)-HETE in the development of angiotensin
II-dependent hypertension.9
Several lines of evidence support a role for 12(S)-HETE
in essential hypertension. First, an enhanced platelet 12(S)-
HETE production has been observed in the spontaneously
hypertensive rat (SHR).10 Second, 12-LOX inhibition has
been shown to produce a dose-dependent hypotensive effect
in SHR.11 Finally, we recently reported that urinary excretion
and platelet production of 12(S)-HETE are increased in
patients with essential hypertension.12
From the evidence exposed above, the human 12-LOX
gene (ALOX12) is a plausible candidate gene for human
essential hypertension. The aim of this study was to search
for genetic variants in the human ALOX12 gene in order to
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find putative functional polymorphisms to be tested for
association with essential hypertension. Furthermore, we
aimed to test whether nonsynonymous polymorphisms in
conserved regions of the gene are associated with the urinary
excretion of its product, 12(S)-HETE, in patients with
essential hypertension.
RESULTS
The analysis included 200 patients with essential hyperten-
sion, 103 women (51.5%) and 97 men (48.5%), aged 5671
years old, with a mean systolic blood pressure (SBP) of
17371 mmHg and a mean diastolic blood pressure (DBP)
of 10571 mmHg, and with a mean body mass index (BMI)
of 2870.4 kg/m2. The normotensive control group consisted
of 166 subjects, 75 (45%) women and 91 (55%) men aged
5471 years, with a mean SBP of 11771 mmHg and a mean
DBP of 6971 mmHg, and with a mean BMI of 2470.5 kg/
m2. There were no differences between groups with respect to
gender distribution (P¼ 0.136) and age (P¼ 0.07). As
expected, there were significant differences in SBP (Po0.001),
DBP (Po0.001) and BMI (Po0.01) between groups.
Table 1 shows the distribution of genotypes for the
ALOX12 polymorphisms tested, which did not deviate from
Hardy–Weinberg equilibrium in patients and in controls.
Specifically, for the functional R261Q polymorphism (3957
G4A), assuming a frequency of 0.621 for the G allele and of
0.379 for the A allele, the distribution of genotypes was
in agreement with Hardy–Weinberg equilibrium either
in hypertensives (w2¼ 5.28, P40.05) or in controls
(w2¼ 3.43, P40.1).
As shown in the table, there was a significant difference in
the distribution of genotypes of the R261Q (3957 G4A)
polymorphism between patients and controls, with lower
frequency of GG genotype and higher frequency of AA
genotype in the controls. Accordingly, the allele frequency
distribution was significantly different between patients
(G¼ 0.67; A¼ 0.33) and controls (G¼ 0.57; A¼ 0.42),
w2¼ 7.625, Po0.01.
Due to the potential functional properties of the R261Q
polymorphism, we selected two intronic polymorphisms in
order to test the genotype distribution between patients and
controls. These polymorphisms were 1559 C4T, which is
located in the same haplotype block according to Haplotype
Map for Caucasians in www.applera.com, and 12185 G4C,
which is located away from the haplotype block mentioned.
As shown in Table 1, there were no differences in genotype
distribution between groups for the 1559 C4T polymorph-
ism and the 12185 G4C polymorphism of ALOX12.
Likewise, there were no differences in the distribution of
allele frequencies (data not shown).
Table 2 shows the SBP, DBP, and mean arterial blood
pressure values according to genotypes in both essential
hypertensives and controls, as well as in the combined
sample. It can be appreciated that no significant differences
were present in blood pressure either in hypertensives or
controls among genotypes of the R261Q, 1559 C4T, and
12185 G4C polymorphisms of the ALOX12 gene. In
contrast, when considering the R261Q polymorphism in
both hypertensives and controls together, there was a trend to
lower the blood pressure in subjects with the AA genotype as
compared to the GG genotype, heterozygotes showing
intermediate values: for SBP GG 14973, GA 14573, AA
14074 (analysis of variance, P¼ 0.190; Kruskall–Wallis,
P¼ 0.254) and for DBP GG 9171.5, GA 8772, AA 8472
(analysis of variance, P¼ 0.057; Kruskall–Wallis, P¼ 0.062).
However, this trend may be explained by the non-normal
distribution of blood pressure in the pooled sample.
Table 1 | Genotype frequency distribution of R261Q (3957 G4A), 1559 C4T, and 12185 G4C variants among patients with
essential hypertension and normotensive controls
ALOX12 variants
Hypertensive patients (n=200) Normotensive controls (n=166)
R261Q GG GA AA GG GA AA P
92 (0.46) 84 (0.42) 24 (0.12) 56 (0.34) 78 (0.47) 32 (0.19) 0.03
C1559T CC CT TT CC CT TT
90 (0.45) 79 (0.40) 31 (0.15) 62 (0.37) 77 (0.47) 27 (0.16) 0.327
G12185C GG GC CC GG GC CC
89 (0.45) 86 (0.43) 25 (0.12) 62 (0.38) 85 (0.51) 19 (0.11) 0.335







R261Q GG GA AA GG GA AA
SBP (mmHg) 17272 17572 17073 11571 11871 12072
DBP (mmHg) 10571 10771 10372 7071 6871 7171
MBP (mmHg) 12871 12971 12672 8571 8571 8771
Combined sample (n=366)a
R261Q GG GA AA
SBP (mmHg) 14973 14573 14074
DBP (mmHg) 9171.6 8771.6 8472.3
MBP (mmHg) 11072 10672 10273
DBP, diastolic blood pressure; MBP, mean arterial blood pressure; SBP, systolic
blood pressure.
aKruskall–Wallis, SBP (P=0.254), DBP (P=0.062), MBP (P=0.125).
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Table 3 shows the clinical characteristics of the patients
with essential hypertension according to the ALOX12 gene
R261Q polymorphism. As can be appreciated, no significant
differences in age, gender, BMI, LVH prevalence, urinary
albumin excretion rate, plasma renin activity, or plasma
aldosterone among genotypes were appreciated. In order to
test whether the R261Q polymorphism influences the
ALOX12 gene product, 12(S)-HETE, in essential hyperten-
sion, we measured the urinary excretion of this metabolite in
patients carrying the AA genotype (N¼ 24) and compared it
to a matched group of consecutive patients with GA and GG
genotypes. We found that in patients with the GG genotype
the urinary excretion of 12(S)-HETE was significantly higher
than in GA or AA patients: 1371.5 vs 8.271.8 vs 871.5 ng/
mg creatinine, respectively, P¼ 0.018 (Figure 1). There were
no differences in age, gender distribution, BMI, and blood
pressure between the GG and AA patients selected (data not
shown). On the other hand, there were no differences in the
urinary excretion of 12(S)-HETE among the genotypes of the
intronic polymorphism of ALOX12 (data not shown).
DISCUSSION
In this study, we have analyzed the association between a
frequent polymorphism in the human ALOX12 gene, R261Q
(3957 G4A), with essential hypertension and urinary
excretion of the metabolite 12(S)-HETE. We have shown
that the distribution of R261Q genotypes is significantly
different between patients and controls, with patients
displaying a significantly higher frequency of the G allele.
Urinary excretion of 12(S)-HETE was measured in patients
and significantly higher levels of excretion of this metabolite
were present in G homozygous as compared to GA patients
and A homozygous.
Three different pathways are responsible for arachidonic
acid metabolism: cycloxygenase (COX), LOX, and the
cytochrome P-450. The role of cycloxygenase or cytochrome
P-450 metabolites in cardiovascular physiology and hyper-
tension has been intensively studied in the last years.13,14 For
instance, a P-450 metabolite, 20-HETE, acting on the one
hand as an important vasoconstrictor of renal vessels
(mediating angiotensin II) and on the other hand as an
inhibitor of Na reabsorption in the thick ascending limb of
Henle15 has been shown to be linked to various models of
hypertension by genetic approaches as well by expression
studies.16 Moreover, very recently, a functional polymorph-
ism of CYP4A11 20-HETE synthase has been associated with
human essential hypertension in Caucasians.17
In contrast, the possible role of arachidonic acid metabolites
of the LOX pathway in hypertension has been less explored.
Both animal and human data support ALOX12 as a candidate
gene in essential hypertension. The administration of LOX
inhibitors reduces blood pressure in several rat models of
hypertension.9,11 The vasoconstrictive effects of 12(S)-HETE are
in agreement with its prohypertensive functions.6 Accordingly,
treatment with LOX inhibitors attenuates the vasoconstrictor
action of angiotensin II in hypertensive rats.18 Furthermore,
evidence for increased 12-LOX activity in the SHR has been
provided, with platelet 12(S)-HETE production shown to be
higher than in control WKY rats, with a correlation between
platelet 12(S)-HETE production and SBP only in the SHR.10 In
addition, increased 12(S)-HETE production has also been
demonstrated in the aorta of the SHR.19
The role of 12(S)-HETE in human hypertension has been
less studied. It has been reported that vascular smooth muscle
and endothelial cells from patients with diabetes mellitus
have increased release of 12- and 15-HETE, suggesting a role
for this metabolite in this disease.14 Furthermore, increased
urinary excretion of 12(S)-HETE has been described in
patients with type II diabetes with incipient nephropathy.20
We recently explored the possible role of 12-LOX in essential
hypertension and showed that the urinary excretion of
12(S)-HETE is increased in patients with this disease as
compared to controls.12 In addition, we demonstrated that
the platelets from patients displayed higher expression of 12-
LOX protein and enhanced production of 12(S)-HETE.12
The origin of urinary 12-HETE has not been fully clarified.
However, urinary concentration of this eicosanoid
probably reflects renal synthesis, since both leukocyte-type
and platelet-type ALOX12 are expressed in renal vessels,
glomeruli, and tubules.2,21 Moreover, available studies have
shown that parenteral tracer 12-HETE is not excreted in
urine.22 From data obtained in animals, we can speculate that
Table 3 | Clinical characteristics of the patients with essential
hypertension according to the ALOX12 gene R261Q (3957
G4A) polymorphism genotypes
Genotype
Variable GG GA AA P
Age 5771 5571 5672 0.503
Gender (M/F) 47/45 35/49 15/9 0.157
BMI (kg/m2) 2871 2771 2971 0.093
LVH prevalence 0.33 0.39 0.59 0.154
UAE (mg/day) 1875 2777 30719 0.561
PRA (ng/ml/h) 0.3370.02 0.4070.08 0.3470.10 0.826
Paldo (pg/ml) 1070.9 1371.1 1371.3 0.078
BMI, body mass index; LVH, left ventricular hypertrophy; Paldo, plasma aldosterone;























Figure 1 | Urinary levels of 12(S)-HETE according to the ALOX12
gene R261Q polymorphism genotypes. Two-tailed Kruskal–Wallis
test.
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increased renal 12-HETE production (probably in preglo-
merular arteries) may be linked to hypertension through
renal vasoconstriction. To our knowledge, this is the first
evaluation for functional polymorphisms in the 12-LOX gene
(ALOX12) to be tested for association with human essential
hypertension. Of the six exonic polymorphisms described in
ALOX12, only R261Q (3957 G4A) predicts a nonconserva-
tive amino-acid change that is located in the LOX domain,
one of the most important and conserved regions in this
protein. Therefore, it is predicted to produce changes in the
enzyme activity. The relevance of the R261Q (3957 G4A)
genetic variation in ALOX12 to hypertension is supported by
the significant association of the GG genotype with essential
hypertension and higher urinary excretion of 12(S)-HETE
found in our sample of patients. We did not observe
differences in blood pressure among genotypes in patients or
controls. This discrepancy could be explained because we
determined office blood pressure rather than ambulatory
blood pressure monitoring, which would have decreased the
variability of this parameter. In contrast, when patients and
controls were pooled together, there was a trend to lower
DBP in AA vs GG subjects, likely influenced by the non-
normal distribution of blood pressure in the pooled sample.
It is possible that the selection of a larger, population-based
cohort would overcome this limitation of the present study.
An alternative explanation to this discrepancy may be that
increased 12-HETE could be a reflection of the atherosclerotic
process that is frequently present in hypertensive patients. A
support for this possibility is the convincing demonstration by
targeted deletion experiments that 12-LOX actively partici-
pates in the development of atherosclerosis.23,24
In conclusion, although the precise role of 12(S)-HETE in
the development of human hypertension remains to be
clarified, the results of the present study suggest that a
genetically influenced alteration in the activity of ALOX12
may participate in this polygenic disorder. In contrast to the
physiologic and biochemical evidence of the participation of
12-HETE in experimental hypertension, no genetic data in
animals regarding ALOX12 are, to our knowledge, yet
available. It is evident that our results strongly support
further study of the relationship of variants in this gene with
hypertension and levels of 12(S)-HETE in other populations.
MATERIALS AND METHODS
Study subjects
A total of 200 patients with essential hypertension were consecu-
tively recruited from the outpatient clinic of the Nephrology Service,
Hospital Clı´nic, Barcelona (Spain). The diagnosis of essential
hypertension was considered on the basis that no known cause of
high blood pressure could be detected after complete clinical,
biochemical, and radiological examination. The following selection
criteria were applied: (a) age between 25 and 80 years, (b) family
history of hypertension in at least one first-degree relative, (c)
absence of diabetes mellitus, (d) BMI o45 kg/m2 and (e) alcohol
intake o50 g/day. In addition, patients on oral contraceptives were
excluded. None of the patients had renal impairment (serum
creatinine4132 mmol/l), cardiac failure or evidence of coronary
heart disease, stroke, or peripheral vascular disease. All the patients
had at least three office blood pressure measurements above 140/
90 mmHg after 4 weeks of an unrestricted salt diet and without
antihypertensive medication. The local Ethics Committee approved
the study and an informed consent was obtained from all the
participants. Patients and controls were maintained on a normal
caloric diet with a sodium intake of approximately 100 mmol/day.
Mean arterial blood pressure was calculated as the diastolic pressure
plus one-third the pulse pressure. BMI was calculated as weight
(kg)/height2 (m). In all, 166 matched control subjects aged from 25
to 80 years, with SBPo130 mmHg and DBPo80 mmHg on three
separate occasions, and no history of hypertension or cardiovascular
disease (diabetes mellitus, ischemic heart disease, stroke, or
peripheral vascular disease), were selected as normotensive controls.
All individuals included in the study were Caucasian.
Genotyping of the ALOX12 polymorphisms
An extensive search of genome databases (www.ncbi. nlm.nih.gov/
SNP/) was performed to find the single-nucleotide polymorphisms
(SNPs) that have been informed within the ALOX12 gene. Of the up
to 40 SNPs informed in the human ALOX12 gene, only six are
located in exons. Of these exonic SNPs, only four are nonsynon-
ymous; that is, they produce a change in the amino-acid sequence:
K259E, R261Q, S322N and H430R, corresponding to the National
Center for Biotechnology Information (NCBI) SNP cluster IDs
rs4987104, rs1126667, rs434473, and rs11571342, respectively.
K259E produced a change of a basic side-chain amino acid (K) to
an acidic side-chain amino acid (E). However, the frequency of the
rare allele is reported to be 0.005. S322N and H430R were considered
to be nonrelevant because they determine conservative substitutions
within the same group of amino acids (uncharged side-chain amino
acid S4N and basic side-chain amino acid H4R). Finally, R261Q
produced a change from a basic side-chain amino acid R to an
uncharged polar side-chain amino acid (Q) and, in addition, is
located in a conserved domain of the enzyme. Therefore, this
polymorphism was considered to be potentially important and was
used in the case–control analysis. In addition, two intronic
polymorphisms were also used for the association analysis.
R261Q polymorphism (3957 G4A, exon 6, NCBI SNP
#rs1126667). DNA was extracted from 10 ml of whole blood by
saline precipitation according to standard procedures. Polymerase
chain reaction (PCR) was conducted in a 25 ml volume reaction
containing 20 mM Tris-HCl (pH¼ 8.4), 50 mM KCl, 2.1 mM MgCl2,
200 mM deoxynucleoside triphosphates, 0.8mM each primer, 1 U
Taq polymerase (Boehringer Mannheim, Germany), and 100 ng of
genomic DNA. The primer pair used for PCR amplification was
50-CTG GCA GGA TGA TGA GTT GTT-30 (sense) and 50-AGT ACT
GCA GCC TTC CTC TG-30 (antisense), as reported previously. After
a denaturation step at 951C for 5 min, PCR was conducted for 34
cycles with denaturation at 951C for 45 s, annealing at 601C for 30 s
and extension at 721C for 30 s, with a final extension step at 721C for
5 min. The PCR product (244 base pairs (bp)) was digested with the
restriction enzyme BanII (New England Biolabs, Ipswich, MA, USA)
and electrophoretically resolved on 7% acrylamide and visualized
under ultraviolet illumination. The GG genotype appears as a 122-bp
band, while the AA genotype appears as 244- and 127-bp bands.
Heterozygous GA subjects showed all three bands. The genotype
determination was checked by automatic sequencing and was
performed in a blinded fashion.
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Polymorphism 1559 C4T (intron 2, NCBI SNP
#rs2070589). DNA was extracted from 10 ml of whole blood by
saline precipitation according to standard procedures. PCR was
conducted in a 25-ml volume reaction containing 20 mM Tris-HCl
(pH¼ 8.4), 50 mM KCl, 1.5 mM MgCl2, 200mM deoxynucleoside tripho-
sphates, 0.8mM each primer, 1 U Taq polymerase (Boehringer Mannheim,
Germany), and 100 ng of genomic DNA. The primer pair used for PCR
amplification was 50-CTT GGG GCT CCT GCA GTT CGT GA-30
(sense) and 50-TGC GGG CCA GTG TGC TTC TTG TC-30 (antisense).
After a denaturation step at 961C for 5 min, PCR was conducted for 34
cycles with denaturation at 961C for 30 s, annealing at 581C for 30 s and
extension at 721C for 30 s, with a final extension step at 721C for 5 min.
The PCR product was digested with the restriction enzyme BsaH1 (New
England Biolabs, USA) and electrophoretically resolved on 2% agarose
and visualized under ultraviolet illumination. The TT genotype appears
as a 663-bp band, while the digested pattern of CC genotype appears as
481- and 182-bp bands. Heterozygous CT subjects showed all three
bands. The genotype determination was checked by automatic
sequencing and was performed in a blinded fashion.
Polymorphism 12185 G4C (intron 12, NCBI SNP
#rs438444). DNA was extracted from 10 ml of whole blood by
saline precipitation according to standard procedures. PCR was
conducted in a 25-ml volume reaction containing 20 mM Tris-HCl
(pH¼ 8.4), 50 mM KCl, 1.5 mM MgCl2, 200mM deoxynucleoside
triphosphates, 0.8 mM each primer, 1 U Taq polymerase (Boehringer
Mannheim, Mannheim, Germany), and 100 ng of genomic DNA.
The primer pair used for PCR amplification was 50-TCC CTC CGA
AGC CCA CAA G-30 (sense) and 50-ACC TCC GCC TCC CAA GTT
C-30 (antisense). After a denaturation step at 961C for 5 min, PCR
was conducted for 34 cycles with denaturation at 961C for 30 s,
annealing at 601C for 30 s and extension at 721C for 30 s, with a final
extension step at 721C for 5 min. The PCR product (244 bp) was
digested with the restriction enzyme BanII (New England Biolabs,
USA) and electrophoretically resolved on 7% acrylamide and
visualized under ultraviolet illumination. The GG genotype appears
as 231-, 148-, and 127-bp bands, while the CC genotype appears as
379- and 127-bp bands. Heterozygous GA subjects showed all the
above-mentioned bands. The genotype determination was checked
by automatic sequencing and was performed in a blinded fashion.
Determination of urinary 12(S)-HETE
The levels of 12(S)-HETE in urine were measured by enzyme-linked
immunosorbent assay (DRG Diagnostica, Marburg, Germany) after
extraction of samples on Sep-Pak C18 cartridges (Waters, Milford, MA,
USA) following the directions of the manufacturer. The 12-HETE
enzyme-linked immunosorbent assay is specific for 12(S)-HETE, with
less than 2.5% crossreactivity with 12(R)-hydroxyeicosatetraenoic acid,
0.3% with 15-HETE, 0.2% with 5-HETE, 0.1% with prostaglandin E2,
and 0.1% with prostaglandin I2. This system has been previously
validated and compared with HPLC by our group. The determination
of urinary 12(S)-HET was performed in a blinded fashion in duplicates.
Urinary creatinine was measured by an automatic analyzer. Urinary
albumin excretion rate from two separate 24-h urine collections was
measured using an immunonephelometric assay (Boehringer Man-
nheim, Mannheim, Germany). Microalbuminuria was defined as a
urinary albumin excretion rate between 30 and 300 mg/day.
Statistical analysis
Data are presented as mean7s.e.m. Comparisons between means
were determined by analysis of variance or by two-sided
Kruskall–Wallis test for unpaired data or t-test where appropriate.
Comparisons between genotype distributions were carried out with
w2. Correlation coefficients were calculated by the least-squares
method. The 5% probability level was regarded as significant.
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